As previously reported, Guggenheim analyst Yatin Suneja upgraded Zogenix to Buy from Neutral after speaking with management following the news on Fintepla NDA resubmission in Dravet in Q3. The analyst believes the company has a clear understanding with the FDA on potential approval pathway and views the news as the best case scenario. The company also announced the loss of breakthrough designation, which is surprising but in line with FDA policy, he notes, adding however, that it does not change his view on the approvability of the drug and thinks priority review could help with a speedy approval. Suneja also raised his price target on the shares to $64 from $40.